Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations.

Thin filament hypertrophic cardiomyopathy (HCM) mutations increase myofilament Ca2+- sensitivity and alter Ca2+ handling and buffering. The myosin inhibitor mavacamten reverses the increased contra...